Comparative Pharmacology
Head-to-head clinical analysis: COACTIN versus PYLERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COACTIN versus PYLERA.
COACTIN vs PYLERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Coactin (mecillinam) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2) in gram-negative bacteria, leading to the formation of spheroplasts and cell lysis.
Bismuth subsalicylate is a salicylate with antimicrobial and anti-inflammatory properties. It inhibits the growth of Helicobacter pylori by binding to the bacterial cell wall, disrupting cell membrane integrity, and inhibiting urease activity. It also reduces gastric inflammation via prostaglandin inhibition.
400 mg orally every 6-8 hours with a full glass of water.
4 capsules (bismuth subcitrate potassium 420 mg, metronidazole 375 mg, tetracycline 375 mg) orally four times daily (after meals and at bedtime) for 10 days.
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment; clinically requires frequent dosing or dose adjustment in renal failure.
Terminal half-life ~6-8 hours; in renal impairment, prolonged up to 20 hours
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: less than 10% as metabolites and unchanged drug.
Renal: 60-80% as unchanged drug; Fecal: 20-40%; Biliary: minor (<5%)
Category C
Category C
Antibiotic Combination
Antibiotic Combination